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In recent years, small molecules and anti-
bodies targeted against oncogenic pro-
teins have proven to be effective
antitumor agents. These molecularly tar-
geted agents, Gleevec, Herceptin, and
Iressa, have raised hopes that an effec-
tive and generally applicable strategy for
reversing tumor growth may be disruption
of the biochemical functions of
oncoproteins (Druker, 2002).
These oncogenic proteins are
produced by activating muta-
tions in proto-oncogenes.
Extensive resources are
being deployed in efforts to
discover small molecules or
antibodies that inhibit onco-
proteins, particularly those
that function biochemically as
kinases (Shawver et al.,
2002).
This strategy would not
appear, on its face, to be
applicable to tumor suppres-
sors, which are frequently
mutated or deleted in tumor
cells (Hansen and Cavenee,
1988). When a tumor sup-
pressor protein is present in a
mutated form, it is conceiv-
able, albeit unlikely, that the
normal function of the protein
can be restored by a small
molecule that binds to the
mutant protein and causes an
appropriate conformational
change. However, when a
tumor suppressor gene has
been deleted from the
genome of a tumor cell, using
a small molecule to restore
the function of the encoded
tumor suppressor protein
appears to be a near-impos-
sible task. In such circum-
stances, because the
encoded protein is entirely
lacking from tumor cells, it is
necessary to find a small mol-
ecule that replaces partially or complete-
ly the biochemical function of the missing
protein.
In this issue of Cancer Cell, however,
Kau et al. (2003) demonstrate that it is
possible to restore at least one function
of the tumor suppressor PTEN using
small organic molecules in cells that lack
PTEN.This result suggests a strategy for
reversing the consequences of deletions
of tumor suppressor genes, namely (1)
determining the cellular functions of the
encoded tumor suppressor proteins, (2)
developing high-throughput screens for
small molecules that restore these cellu-
lar functions via interaction with down-
stream proteins, and (3) elucidating the
mechanisms of action of such com-
pounds using information about signal-
ing networks upstream and downstream
of the missing tumor suppressor protein.
The tumor suppressor protein select-
ed for study by Kau et al. was PTEN, a
lipid phosphatase that is a negative reg-
ulator of PI3K- and Akt-dri-
ven cell proliferation (Sulis
and Parsons, 2003). PTEN
functions biochemically by
dephosphorylating lipid
phosphates that are products
of PI3K phosphorylation.
FOXO1a restrains cell growth
and it is normally unable to
do so in the absence of
PTEN (Burgering and
Medema, 2003).
In PTEN null cells,
FOXO1a is inactivated by
PI3K-dependent phosphory-
lation; Akt phosphorylates
FOXO transcription factors at
multiple sites. Phosphorylated
FOXO1a is inappropriately
localized to cytoplasm and
prevented from restraining
cell cycle progression. Kau et
al. reasoned that relocaliza-
tion of FOXO1a to the nucleus
would reverse consequences
of PTEN deletion and the
tumorigenicity of PTEN null
cells. These investigators per-
formed a high-throughput
chemical screen to identify
inhibitors of nuclear export of
FOXO1a in PTEN-deficient
tumor cells. In these cells,
transfected FOXO1a has a
cytosolic localization.
Compounds that relocalized
FOXO1a to the nucleus were
discovered and are of interest
for their ability to possibly
reverse consequences of
PTEN deficiency.
The authors found a series of com-
pounds, from among 18,000 tested,
exhibiting the desired activity. These
compounds were categorized in sec-
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Developing small molecule inhibitors of oncoproteins, which are activated in tumor cells, is a newly popular strategy for
cancer-related drug discovery.The complementary strategy, developing small molecules that restore the function of miss-
ing tumor suppressors, is much more difficult to realize. However, in this issue of Cancer Cell, Kau et al. report the discov-
ery of small molecules that reverse some cellular consequences of the loss of the tumor suppressor PTEN.
Figure 1. Chemical genetic analysis of PTEN-regulated Fox01a
localization.
Kau et al. performed a high-throughput chemical screen for small
molecules that localize Fox01a to the nuclei of PTEN-deficient cells.
PTEN functions as a lipid phosphatase upstream of Akt, a kinase that
phosphorylates Fox01a and thereby regulates its nuclear localization.
The screen revealed both compounds that were PTEN/Akt/Fox01a-
pathway-specific and compounds that were general nuclear export
inhibitors. The pathway-specific compounds therefore reverse at least
one consequence of PTEN deficiency in tumor cells.
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ondary screens as (1) general nuclear
export inhibitors or (2) PI3K/Akt path-
way-specific export inhibitors. Many of
the general export inhibitors reacted with
the nuclear export receptor CRM1,
which binds nuclear export sequences of
proteins and exports them into the cyto-
plasm. A known inhibitor of CRM1 is lep-
tomycin B, which inactivates CRM1 by
covalently labeling cysteine 528 (Kudo et
al., 1999; Nishi et al., 1994).
The general export inhibitors inter-
fered with CRM1 function and nonspecif-
ically blocked export of proteins with
nuclear export sequences. All 19 general
export inhibitors were found to target
cysteine 528 in CRM1, in a manner
seemingly identical to leptomycin B.
Inspection of the chemical structures of
these compounds reveals that they con-
tain electrophilic functionalities, such as
Michael acceptors, just as leptomycin B
does. This important observation sug-
gests that in the future, compounds
found to inhibit export of proteins should
be inspected for α,β-unsaturated car-
bonyls, or other thiol-reactive elec-
trophilic functionality, to determine
whether such compounds may be acting
as CRM1 inhibitors.
The pathway-specific FOXO1a-
export inhibitors inhibited FOXO1a
export but did not alter export of an unre-
lated protein. Additional epistasis experi-
ments revealed that some of these
compounds act upstream of Akt and oth-
ers act downstream of Akt.This chemical
genetic screen and subsequent analysis
is an example of the utility of the chemi-
cal genetic approach (Stockwell, 2000)
in which the functions of novel small mol-
ecules are analyzed systematically by
measuring their affects on proteins and
signaling pathways. This approach is
strengthened by exploiting knowledge
about existing biologically active mole-
cules and comparing them to newly iden-
tified compounds (Root et al., 2003).
Moreover, the use of a phenotypic
change as an output enables identifica-
tion of small molecules that target multi-
ple components of a signaling pathway
and yet result in a desired effect.
Thus, the comparison of compounds
identified in the primary screen to the
existing nuclear export inhibitor lepto-
mycin B revealed a CRM1-dependent
mechanism of action for numerous gen-
eral export inhibitors. Because many of
these compounds are synthetically pre-
pared small molecules with few stere-
ogenic centers, they may serve as more
accessible, less toxic, and more stable
leptomycin B substitutes. In addition,
they provide scaffolds and cysteine-
reactive functional groups that can be
used to develop potent CRM1 inhibitors.
Systematic classification of identified
FOXO1a nuclear export inhibitors based
on their behavior in secondary assays
allowed Kau et al. to determine the role
of calmodulin in regulating FOXO1a sig-
naling. The authors discovered that
calmodulin inhibitors such as phenoth-
iazines identified in the screen, along
with structurally unrelated calmodulin
inhibitors W-13, calmidazolium, and
ophiobolin A, relocalized FOXO1a to
nucleus. These results highlight the
value of screening both known and novel
compounds; such a strategy facilitates
identification of molecular targets and
provides a basis for structure-function
analysis.
An important aspect of these investi-
gations is that they involved both
chemists and biologists in the analysis of
the screen. Such cooperation proved
essential to the correct interpretation of
the mode of action of the general export
inhibitors; the recognition of Michael-
type electrophilic functionality likely sug-
gested these compounds should be
tested for their dependence on cysteine
528 in CRM1. Although the notion of mul-
tidisciplinarity is often touted, it is rarely
implemented, due to institutional and
cultural barriers. Those groups that are
able to surmount such chasmal divides
will be the ones to reap the benefits of
the chemical genetic approach.
Finally, these investigations demon-
strate that small molecules can be used
to reverse consequences of the loss of a
tumor suppressor gene. By selecting
compounds that restore nuclear
FOXO1a localization in PTEN null cells,
Kau et al. were able to identify small
molecules that target multiple steps in
the PI3K/PTEN/Akt signaling pathway.
Such an unbiased screening approach
is particularly valuable for exploring
novel targets for therapy within signaling
pathways. Because loss of tumor sup-
pressors is a major component of
tumorigenicity, this strategy might prove
to be a powerful one for reversing the
consequences of genetic changes in
tumor cells.
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